These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 20631407)

  • 1. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.
    Isakova T; Gutiérrez OM; Smith K; Epstein M; Keating LK; Jüppner H; Wolf M
    Nephrol Dial Transplant; 2011 Feb; 26(2):584-91. PubMed ID: 20631407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.
    Isakova T; Barchi-Chung A; Enfield G; Smith K; Vargas G; Houston J; Xie H; Wahl P; Schiavenato E; Dosch A; Gutiérrez OM; Diego J; Lenz O; Contreras G; Mendez A; Weiner RB; Wolf M
    Clin J Am Soc Nephrol; 2013 Jun; 8(6):1009-18. PubMed ID: 23471131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients.
    Soriano S; Ojeda R; Rodríguez M; Almadén Y; Rodríguez M; Martín-Malo A; Aljama P
    Clin Nephrol; 2013 Jul; 80(1):17-22. PubMed ID: 23391319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.
    Ureña-Torres P; Prié D; Keddad K; Preston P; Wilde P; Wan H; Copley JB
    BMC Nephrol; 2014 May; 15():71. PubMed ID: 24885942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.
    Chang YM; Tsai SC; Shiao CC; Liou HH; Yang CL; Tung NY; Hsu KS; Chen IL; Liu MC; Kao JL; Jhen RN; Huang YT
    Clin Exp Nephrol; 2017 Oct; 21(5):908-916. PubMed ID: 27928636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.
    Gonzalez-Parra E; Gonzalez-Casaus ML; Galán A; Martinez-Calero A; Navas V; Rodriguez M; Ortiz A
    Nephrol Dial Transplant; 2011 Aug; 26(8):2567-71. PubMed ID: 21436379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperphosphataemia: treatment options.
    Malberti F
    Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of phosphate binders in moderate CKD.
    Block GA; Wheeler DC; Persky MS; Kestenbaum B; Ketteler M; Spiegel DM; Allison MA; Asplin J; Smits G; Hoofnagle AN; Kooienga L; Thadhani R; Mannstadt M; Wolf M; Chertow GM
    J Am Soc Nephrol; 2012 Aug; 23(8):1407-15. PubMed ID: 22822075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease.
    Houston J; Smith K; Isakova T; Sowden N; Wolf M; Gutiérrez OM
    J Ren Nutr; 2013 Jan; 23(1):12-20. PubMed ID: 22406119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease.
    Goto S; Nakai K; Kono K; Yonekura Y; Ito J; Fujii H; Nishi S
    Clin Exp Nephrol; 2014 Dec; 18(6):925-31. PubMed ID: 24578219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding.
    Pennick M; Poole L; Dennis K; Smyth M
    Ren Fail; 2012; 34(3):263-70. PubMed ID: 22250993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
    Adema AY; de Borst MH; Ter Wee PM; Vervloet MG;
    J Ren Nutr; 2014 May; 24(3):143-50. PubMed ID: 24216259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C; Roe K; Lehman E; Verma N
    Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
    Ix JH; Isakova T; Larive B; Raphael KL; Raj DS; Cheung AK; Sprague SM; Fried LF; Gassman JJ; Middleton JP; Flessner MF; Block GA; Wolf M
    J Am Soc Nephrol; 2019 Jun; 30(6):1096-1108. PubMed ID: 31085679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.
    Sprague SM; Abboud H; Qiu P; Dauphin M; Zhang P; Finn W
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):178-85. PubMed ID: 19056618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
    Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
    J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.
    Wilson R; Zhang P; Smyth M; Pratt R
    Curr Med Res Opin; 2009 Dec; 25(12):3021-8. PubMed ID: 19845495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fortified phosphorus‑lowering treatment through administration of lanthanum protects against vascular calcification via regulation of FGF23 in chronic kidney disease.
    Jiang J; Li Y; Zheng D; Wang Z; Zhou H; Liu G
    Int J Mol Med; 2020 Nov; 46(5):1783-1793. PubMed ID: 32901861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.